Publication | Closed Access

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Cancer ImmunosurveillanceMedicineImmunologyPd-1/pd-l1 InhibitorsCancer GenomicsImmune Checkpoint InhibitorHead And Neck CancerImmunotherapyMolecular DiagnosticsRadiation OncologyActive PhenotypeLung CancerGene Expression Profiling